U.S. hospitals have been slow to embrace Covid-19 antibody drugs from Eli Lilly and Co. and Regeneron Pharmaceuticals Inc. that were authorized to reduce the risk of hospitalization, U.S. officials said.
Regeneron Pharmaceuticals Inc. paused patient enrollment in two clinical studies testing the company’s experimental lymphoma drug, after the U.S. health regulator requested changes in trial protocols.
Sanofi and Regeneron’s Dupixent product won approval from the European Commission to treat children aged 6-11 years suffering from severe atopic dermatitis, often known as eczema.
U.S. health officials and politicians pleaded with Americans to stay at home over the Thanksgiving holiday and abide by constraints placed on social and economic life as record coronavirus caseloads pushed hospitals to their limits.
U.S. Surgeon General Jerome Adams pleaded with Americans to grasp “the severity of the moment” and remain vigilant against the coronavirus pandemic, as record hospitalizations pushed healthcare professionals to the brink.
The U.S. government will start distributing Regeneron Pharmaceuticals Inc.’s newly authorized Covid-19 antibody combination on Nov. 24, beginning with more than 30,000 treatment courses, a health official said.
The U.S. Food and Drug Administration issued emergency use authorization for Regeneron Pharmaceuticals Inc.’s Covid-19 antibody therapy, an experimental treatment given to U.S. President Donald Trump that he said helped cure him of the disease.
U.S. hospitals, weighing high demand and tight supplies, said they may limit use of the new Eli Lilly and Co. nantibody drug bamlanivimab to Covid-19 patients with multiple risk factors for serious illness or to those whose immune systems have not begun to fight the infection.
U.S. regulators authorized emergency use of the first experimental antibody drug for Covid-19 in patients who are not hospitalized but are at risk of serious illness because of their age or other conditions.
Regeneron Pharmaceuticals Inc.’s coronavirus antibody cocktail – the experimental treatment that U.S. President Donald Trump received – significantly reduced medical visits in a trial of nearly 800 patients with mild-to-moderate Covid-19.